IELSG37 - A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell
People
Zucca E.
(Responsible)
Additional information
Acronym
IELSG37
Start date
01.04.2013
End date
31.03.2016
Duration
36 Months
Funding sources
SNSF
Status
Ended
Category
Swiss National Science Foundation /
Project Funding /
Mathematics, Natural and Engineering Sciences (Division II)
